Introduction
Eraxis is an antifungal medication. It is used in the treatment of severe fungal infections. It kills the fungi that cause infections and thus provides relief.
Eraxis is administered as an injection by a healthcare professional. Kindly do not self administer. Do not skip any doses and finish the full course of treatment even if you feel better. Your liver function should be monitored regularly during treatment.
It may lead to a few common side effects like decreased potassium levels in the blood, nausea, diarrhea, headache, and vomiting. You may also notice some injection site reactions like pain, swelling or redness. Inform your doctor if these side effects persist for a longer duration. Please consult your doctor if you are pregnant, planning to conceive or breastfeeding.
Side effects of Eraxis
Common
- Decreased potassium level in blood
- Nausea
- Diarrhea
- Headache
- Vomiting
- Fever
- Anemia (low number of red blood cells)
- Insomnia (difficulty in sleeping)
- Indigestion
How to use Eraxis
Your doctor or nurse will give you this medicine. Kindly do not self administer.
How Eraxis works
Eraxis kills fungus by preventing them from making their protective covering.
What if you forget to take Eraxis?
If you miss a dose of Eraxis, please consult your doctor.
Indication
Oesophageal candidiasis, Invasive candidiasis, Candidaemia, Candida infections (intra-abdominal abscess, pertonitis)
Administration
IV Preparation
Reconstitute each 50 mg vial w/ sterile water for inj 15 mL, or each 100 mg vial w/ sterile water for inj 30 mL to provide a concentration of 3.33 mg/mL. Further dilute the reconstituted solution w/ either dextrose inj 5% or sodium chloride inj 0.9% to obtain a solution containing 0.77 mg/mL.
Adult Dose
Intravenous
Oesophageal candidiasis
Adult: Loading dose of 100 mg on day 1, then 50 mg once daily thereafter. Continue treatment for at least 14 days and for at least 7 days following resolution of symptoms. To be given by IV infusion. Max infusion rate: 1.1 mg/min.
Invasive candidiasis, Candidaemia, Candida infections (intra-abdominal abscess, pertonitis)
Adult: Loading dose of 200 mg on day 1, then 100 mg once daily thereafter. Continue treatment for at least 14 days after the last positive culture. To be given by IV infusion. Max infusion rate: 1.1 mg/min.
Renal Dose
No dosage adjustment needed.
Contraindication
Hypersensitivity to anidulafungin or other echinocandins.
Mode of Action
Anidulafungin is a semi-synthetic echinocandin antifungal. It inhibits 1, 3-beta-D-glucan synthesis, an essential component of the fungal cell walls. It has been shown to have in vitro activity against many Aspergillus spp and Candida spp.
Precaution
Patients w/ serious underlying conditions receiving multiple concomitant medications w/ anidulafungin may experience hepatic abnormalities e.g. hepatitis, hepatic dysfunction or worsening hepatic failure. Pregnancy and lactation.
Lactation
There are no data on presence of drug in human milk, effects on breastfed infant or on milk production; drug was found in milk of lactating rats; developmental and health benefits of breastfeeding should be considered along with mother’s clinical need for therapy and any potential adverse effects on breastfed child from therapy or from underlying maternal condition
Side Effect
1-10%
Candidemia treatment
Diarrhea (3%)
Hypokalemia (3%)
Abnl LFTs (2%)
Esophageal Candidiasis treatment
Headache (1%)
Nausea (1%)
Neutropenia (1%)
Rash (1%)
Frequency Not Defined
Possible histamine-mediated symptoms reported including rash, urticaria, flushing, pruritus, bronchospasm, dyspnea, and hypotension; infrequent when infusion rate does not exceed 1.1 mg/minute.
Pregnancy Category Note
Pregnancy
Based on findings from animal studies, therapy can cause fetal harm when administered to a pregnant woman; there are no available human data on use in pregnant women to inform a drug-associated risk of adverse developmental outcomes
Lactation
There are no data on presence of drug in human milk, effects on breastfed infant or on milk production; drug was found in milk of lactating rats; developmental and health benefits of breastfeeding should be considered along with mother’s clinical need for therapy and any potential adverse effects on breastfed child from therapy or from underlying maternal condition